Casein kinase 2 inhibition modulates the DNA damage response but fails to radiosensitize malignant glioma cells

International Journal of Oncology

Volumn 41, Issue 2, 2012, Pages 776-782

  Kroonen, Jérôme ^a   Artesi, Maria ^a   Capraro, Valérie ^a   Nguyen Khac, Minh Tuan ^a   Willems, Marie ^a   Chakravarti, Arnab ^b   Bours, Vincent ^a   Robe, Pierre A ^a,b,c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Casein kinase 2; Glioblastoma; Radiation therapy

Indexed keywords

APIGENIN; CASEIN KINASE II; HISTONE H2AX; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVITY; ENZYME INHIBITION; GAMMA IRRADIATION; GLIOBLASTOMA; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIOSENSITIZATION;

ANALYSIS OF VARIANCE; APIGENIN; CASEIN KINASE II; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVATION; GENE KNOCKDOWN TECHNIQUES; GLIOMA; HUMANS; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RNA INTERFERENCE; STATISTICS, NONPARAMETRIC;

EID: 84863568651     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1489     Document Type: Article

References (56)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005. (Pubitemid 40349501)
2. Robe PA, Bentires-Alj M, Bonif M, et al: In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res 10: 5595-5603, 2004. (Pubitemid 39100501)
3. Bredel M, Scholtens DM, Yadav AK, et al: NFKBIA deletion in glioblastomas. N Engl J Med 364: 627-637, 2011.
4. Squatrito M and Holland EC: DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res 71: 5945-5949, 2011.
5. Becherel OJ, Jakob B, Cherry AL, et al: CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response. Nucleic Acids Res 38: 1489-1503, 2010.
6. Lin YC, Hung MS, Lin CK, et al: CK2 inhibitors enhance the radiosensitivity of human non-small cell lung cancer cells through inhibition of stat3 activation. Cancer Biother Radiopharm 26: 381-388, 2011.
7. Brown MS, Diallo OT, Hu M, et al: CK2 modulation of NF-κB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via Sub-50-nm nanocapsules. Clin Cancer Res 16: 2295-2307, 2010.
8. Eddy SF, Guo S, Demicco EG, et al: Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells. Cancer Res 65: 11375-11383, 2005. (Pubitemid 41823949)
9. Yu M, Yeh J and Van Waes C: Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(s) in head and neck squamous carcinoma cells. Cancer Res 66: 6722-6731, 2006. (Pubitemid 44085630)
10. Siepmann M, Kumar S, Mayer G and Walter J: Casein kinase 2 dependent phosphorylation of neprilysin regulates receptor tyrosine kinase signaling to Akt. PLoS One 5: E13134, 2010.
11. Horejsí Z, Takai H, Adelman CA, et al: CK2 phospho-dependent binding of R2TP complex to TEL2 is essential for mTOR and SMG1 stability. Mol Cell 39: 839-850, 2010.
12. Maccario H, Perera NM, Davidson L, Downes CP and Leslie NR: PTEN is destabilized by phosphorylation on Thr366. Biochem J 405: 439-444, 2007.
13. Kang H, Jung JW, Kim MK and Chung JH: CK2 is the regulator of SIRT1 substrate-binding affinity, deacetylase activity and cellular response to DNA-damage. PLoS One 4: E6611, 2009.
14. Takeishi Y, Ohashi E, Ogawa K, Masai H, Obuse C and Tsurimoto T: Casein kinase 2-dependent phosphorylation of human Rad9 mediates the interaction between human Rad9-Hus1-Rad1 complex and TopBP1. Genes Cells 15: 761-771, 2010.
15. Olsen BB, Issinger OG and Guerra B: Regulation of DNA-dependent protein kinase by protein kinase CK2 in human glioblastoma cells. Oncogene 29: 6016-6026, 2010.
16. Ström CE, Mortusewicz O, Finch D, et al: CK2 phosphorylation of XRCC1 facilitates dissociation from DNA and single-strand break formation during base excision repair. DNA Repair 10: 961-969, 2011.
17. Kaminska B, Ellert-Miklaszewska A, Oberbek A, et al: Efficacy and mechanism of anti-tumor action of new potential CK2 inhibitors toward glioblastoma cells. Int J Oncol 35: 1091-1100, 2009.
18. Prudent R, Moucadel V, Nguyen CH, et al: Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2. Cancer Res 70: 9865-9874, 2010.
19. Pierre F, Chua PC, O'Brien SE, et al: Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol Cell Biochem 356: 37-43, 2011.
20. Battistutta R, Cozza G, Pierre F, et al: Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. Biochemistry 50: 8478-8488, 2011.
21. Schneider CC, Hessenauer A, Montenarh M and Götz C: p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2. Prostate 70: 126-134, 2010.
22. Shehata M, Schnabl S, Demirtas D, et al: Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood 116: 2513-2521, 2010.
23. Li C, Liu X, Lin X and Chen X: Structure-activity relationship of 7 flavonoids on recombinant human protein kinase CK2 holoenzyme. Zhong Nan Da Xue Xue Bao Yi Xue Ban 34: 20-26, 2009.
24. Sarno S, de Moliner E, Ruzzene M, et al: Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl] acetic acid (IQA). Biochem J 374: 639-646, 2003. (Pubitemid 37163909)
25. Zhao M, Ma J, Zhu HY, et al: Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer 10: 104, 2011.
26. Zhong Y, Krisanapun C, Lee SH, et al: Molecular targets of apigenin in colorectal cancer cells: involvement of p21, NAG-1 and p53. Eur J Cancer 46: 3365-3374, 2010.
27. Slusarz A, Shenouda NS, Sakla MS, et al: Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res 70: 3382-3390, 2010.
28. Das A, Banik NL and Ray SK: Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. Cancer 116: 164-176, 2010.
29. Chakravarti A, Zhai GG, Zhang M, et al: Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 23: 7494-7506, 2004. (Pubitemid 39389691)
30. Miyamoto S: Nuclear initiated NF-κB signaling: NEMO and ATM take center stage. Cell Res 21: 116-130, 2010.
31. Keller DM, Zeng X, Wang Y, et al: A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol Cell 7: 283-292, 2001. (Pubitemid 32206496)
32. Tsuchiya Y, Asano T, Nakayama K, Kato T Jr, Karin M and Kamata H: Nuclear IKKbeta is an adaptor protein for IkappaBalpha ubiquitination and degradation in UV-induced NF-kappaB activation. Mol Cell 39: 570-582, 2010.
33. Cheung WL, Turner FB, Krishnamoorthy T, et al: Phosphorylation of histone H4 serine 1 during DNA damage requires casein kinase II in S. cerevisiae. Curr Biol 15: 656-660, 2005.
34. Li J and Stern DF: DNA damage regulates Chk2 association with chromatin. J Biol Chem 280: 37948-37956, 2005. (Pubitemid 41642408)
35. Agullo G, Gamet-Payrastre L, Manenti S, et al: Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol 53: 1649-1657, 1997. (Pubitemid 27356094)
36. Koch CA, Agyei R, Galicia S, et al: Xrcc4 physically links DNA end processing by polynucleotide kinase to DNA ligation by DNA ligase IV. EMBO J 23: 3874-3885, 2004. (Pubitemid 39389718)
37. Quiros S, Roos WP and Kaina B: Rad51 and BRCA2 - new molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS One 6: E27183, 2011.
38. Macrae CJ, McCulloch RD, Ylanko J, Durocher D and Koch CA: APLF (C2orf13) facilitates nonhomologous end-joining and undergoes ATM-dependent hyperphosphorylation following ionizing radiation. DNA Repair 7: 292-302, 2008.
39. Iles N, Rulten S, El-Khamisy SF and Caldecott KW: APLF (C2orf13) is a novel human protein involved in the cellular response to chromosomal DNA strand breaks. Mol Cell Biol 27: 3793-3803, 2007. (Pubitemid 46726186)
40. Zwicker F, Ebert M, Huber PE, Debus J and Weber KJ: A specific inhibitor of protein kinase CK2 delays gamma-H2Ax foci removal and reduces clonogenic survival of irradiated mammalian cells. Radiat Oncol 6: 15, 2011.
41. Neal JA and Meek K: Choosing the right path: does DNA-PK help make the decision? Mutat Res 711: 73-86, 2011.
42. Hill R and Lee PW: The DNA-dependent protein kinase (DNA-PK): more than just a case of making ends meet? Cell Cycle 9: 3460-3469, 2010.
43. Kinner A, Wu W, Staudt C and Iliakis G: Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36: 5678-5694, 2008.
44. Shen J, Channavajhala P, Seldin DC and Sonenshein GE: Phosphorylation by the protein kinase CK2 promotes calpain-mediated degradation of IkappaBalpha. J Immunol 167: 4919-4925, 2001. (Pubitemid 33009721)
45. Viatour P, Merville MP, Bours V and Chariot A: Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation. Trends Biochem Sci 30: 43-52, 2005. (Pubitemid 40093740)
46. Janssens S and Tschopp J: Signals from within: the DNA-damage-induced NF-κB response. Cell Death Differ 13: 773-784, 2006.
47. Kato T, Delhase M, Hoffmann A and Karin M: CK2 is a C-terminal IkappaB kinase responsible for NF-kappaB activation during the UV response. Mol Cell 12: 829-839, 2003. (Pubitemid 37352777)
48. Li N: ATM is required for Ikappa B kinase (IKK) activation in response to DNA double strand breaks. J Biol Chem 276: 8898-8903, 2000.
49. Veuger SJ, Hunter JE and Durkacz BW: Ionizing radiation-induced NF-γB activation requires PARP-1 function to confer radioresistance. Oncogene 28: 832-842, 2008.
50. Hunter JE, Willmore E, Irving JAE, Hostomsky Z, Veuger SJ and Durkacz BW: NF-γB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene 31: 251-264, 2012.
51. Tsuboi Y, Kurimoto M, Nagai S, et al: Induction of autophagic cell death and radiosensitization by the pharmacological inhibition of nuclear factor-kappa B activation in human glioma cell lines. J Neurosurg 110: 594-604, 2009.
52. Berger R, Jennewein C, Marschall V, et al: NF-κB is required for Smac mimetic-mediated sensitization of glioblastoma cells for γ-irradiation-induced apoptosis. Mol Cancer Ther 10: 1867-1875, 2011.
53. Asai A, Miyagi Y, Sugiyama A, et al: Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J Neurooncol 19: 259-268, 1994. (Pubitemid 24296634)
54. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F and Weller M: CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22: 8233-8245, 2003. (Pubitemid 37485516)
55. Meek DW and Cox M: Induction and activation of the p53 pathway: a role for the protein kinase CK2? Mol Cell Biochem 356: 133-138, 2011.
56. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068, 2008.